Polaris Group's (TPE:6550) unit Polaris Pharmaceuticals signed two exclusive regional agreements to commercialize its drug for treating malignant pleural mesothelioma, according to two separate Monday Taiwan Exchange filings.
The first commercialization and channel sales collaboration deal for the drug, dubbed ADI-PEG 20, was signed with Er-Kim Pharmaceuticals. The contract has a term of eight years and covers the EMEA region.
Meanwhile, another commercialization and sales deal was inked with Tabuk Pharmaceutical Manufacturing for the Gulf Cooperation Council market, valid for six years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.